Centre Hospitalier Universitaire de Besancon: Breast Neoplasms trials
The registry lists 13 Breast Neoplasms studies with Centre Hospitalier Universitaire de Besancon as lead sponsor. 4 are open to participants now and 0 have results posted.
Phase 2 1Phase 3 1No phase 11(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- DESIR. Evaluation of the Pre-therapeutic Activity of Dihydropyrimidine dEShydrogenase (DPD) in Patients With Cancer and/or Renal FailureNot yet recruitingNCT07124403
- Evaluation of the Feasibility of a Study Comparing Local Anesthesia and General Anesthesia in Conservative Surgery for Breast CancerNot yet recruitingNCT06910280Not applicable
- FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided TherapyRecruitingNCT06185569
- Relative Dose Intensity of Adjuvant Chemotherapy in Older Women With ER+ HER2- Breast Cancer.Not yet recruitingNCT06010615
- Preferences of Patients Treated With Oral Cancer Drugs and Informal Caregivers for Pharmaceutical Consultation in HospitalCompletedNCT05970471
- Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast CancerStatus unknownNCT05107388Not applicable
- Supervised Exercise, Sleep in Patients With Non Metastatic Breast CancerStatus unknownNCT04867096Not applicable
- IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)CompletedNCT04012229
- Monoclonal Antibodies Elimination in Breast Cancer PatientCompletedNCT02855775Not applicable
- Study of the Anti-tumoral Immune ResponseCompletedNCT02854644Not applicable
- Immune Response for Patients With Metastatic Breast Cancer Treated by EverolimusStatus unknownNCT02854618Not applicable
- Efficacy and Safety of Estracyt® in Metastatic Breast CancerWithdrawnNCT02853071Phase 2
- A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced DiseaseTerminatedNCT02730091Phase 3